NPL-102

N/A

Report date: 2025/09/29 17:45:06

Base Information

Drug NameNPL-102
Drug Alias NameNPL-102
ClassificationBiologics > Biosimilar
Mechanisms of ActionAnti-CTLA4
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovatek Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A